Allred Capital Management LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,167 shares of the biopharmaceutical company’s stock after acquiring an additional 2,055 shares during the period. Allred Capital Management LLC’s holdings in Pfizer were worth $923,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in the company. NewSquare Capital LLC grew its stake in shares of Pfizer by 0.4% during the second quarter. NewSquare Capital LLC now owns 60,418 shares of the biopharmaceutical company’s stock valued at $1,976,000 after acquiring an additional 266 shares in the last quarter. Aevitas Wealth Management Inc. grew its stake in Pfizer by 1.7% in the second quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock worth $520,000 after purchasing an additional 269 shares in the last quarter. Cutter & CO Brokerage Inc. grew its stake in Pfizer by 2.0% in the second quarter. Cutter & CO Brokerage Inc. now owns 13,695 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 274 shares in the last quarter. Beaumont Asset Management L.L.C. grew its stake in Pfizer by 1.3% in the second quarter. Beaumont Asset Management L.L.C. now owns 21,244 shares of the biopharmaceutical company’s stock worth $694,000 after purchasing an additional 276 shares in the last quarter. Finally, Dividend Assets Capital LLC grew its stake in Pfizer by 0.9% in the second quarter. Dividend Assets Capital LLC now owns 30,606 shares of the biopharmaceutical company’s stock worth $1,001,000 after purchasing an additional 278 shares in the last quarter. Institutional investors own 69.08% of the company’s stock.
In other Pfizer news, Director Ronald E. Blaylock purchased 13,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were bought at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at approximately $154,200. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.08% of the company’s stock.
PFE has been the subject of a number of research reports. Mizuho reiterated a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research note on Tuesday, September 15th. Piper Sandler lifted their price target on Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. Berenberg Bank initiated coverage on Pfizer in a research note on Tuesday, September 29th. They issued a “hold” rating and a $38.00 price target for the company. ValuEngine downgraded Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Finally, Atlantic Securities cut shares of Pfizer from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $44.00 to $39.00 in a report on Monday, October 12th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $39.64.
PFE opened at $37.95 on Friday. The business’s 50 day moving average is $36.59 and its 200-day moving average is $36.32. The stock has a market cap of $210.88 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The company had revenue of $11.80 billion for the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.80 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.89 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be issued a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.